{
    "nct_id": "NCT04808453",
    "official_title": "A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-300 Via Intravenous Infusion in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Have a histologically or cytologically confirmed diagnosis of advanced solid tumor\n* Have advanced or metastatic disease refractory to standard curative or palliative therapy or contraindication to standard therapy\n* Have an ECOG performance status of 0-1\n* Have adequate bone marrow reserve, liver and renal function\n* Be reasonably recovered from preceding major surgery or no major surgery within 4 weeks prior to the start of Day 1 treatment\n* Have a negative pregnancy test for females with child bearing age at screening and should not be breast feeding\n* Be willing to abstain from sexual activity or practice physical barrier contraception from study entry to 6 months after the last day of treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have peripheral neuropathy of Grade 3 or Grade 4 at screening\n* Have peripheral sensory neuropathy of Grade 2 or greater at screening\n* Have an interval from previous neurotoxic drugs less than 3 months unless reasonably recovered from all grades of neurotoxicity to grade 1 or lower as judged by the investigator\n* Have known hypersensitivity to chemotherapeutic agents\n* Have chronic diarrhea\n* Have a history of thrombocytopenia with complications including hemorrhage or bleeding > Grade 2 that required medical intervention or any hemolytic condition or coagulation disorders that would make participation unsafe\n* Have unresolved toxicity from previous treatment or previous investigational agents; excluding alopecia\n* Received investigational agents or systemic anticancer agents (other than neurotoxic compounds) within 5 half lives or 28 days, whichever is shorter, prior to Day 1 of treatment\n* Have signs or symptoms of end organ failure, major chronic illnesses other than cancer, or any severe concomitant conditions\n* Have experienced any of the following within the 6-month period prior to screening: angina pectoris, coronary artery disease or cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection fraction less than 40%, or cardiac arrhythmia requiring medical therapy\n* Have other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study\n* Is pregnant or breast-feeding",
    "miscellaneous_criteria": ""
}